Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose finding study of subcutaneous canakinumab for hyperglycemia in metformin-treated type 2 diabetes
2009-009889-13Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Canakinumab + metformin with Placebo + metformin (2 arms). Primary endpoint: Change from baseline in HbA1c at Month 4. Started Apr 2009; status: terminated.
02
Drugs
canakinumab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-009889-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009889-13.